-
Table of Contents
Veterinary Origins of Drostanolone Enantato
Drostanolone enantato, also known as drostanolone enanthate, is a synthetic anabolic-androgenic steroid (AAS) that has been used in the field of sports pharmacology for decades. It is a modified form of dihydrotestosterone (DHT) and is known for its strong androgenic effects, making it a popular choice among bodybuilders and athletes looking to enhance their performance. However, the origins of this powerful substance can be traced back to its use in veterinary medicine.
The Discovery of Drostanolone Enantato
The first mention of drostanolone enantato can be found in a 1959 study by the pharmaceutical company Syntex, where it was referred to as “2α-methyl-5α-androstan-3-one enanthate.” (Syntex 1959) However, it wasn’t until the 1970s that drostanolone enantato gained popularity in the world of sports and bodybuilding.
In 1970, the German pharmaceutical company Schering AG introduced drostanolone enantato under the brand name Masteron. It was initially used in the treatment of breast cancer in women, as it was found to have anti-estrogenic properties. However, it was soon discovered that drostanolone enantato also had strong anabolic effects, leading to its use in the bodybuilding community. (Schering AG 1970)
Veterinary Use of Drostanolone Enantato
While drostanolone enantato gained popularity in the world of sports and bodybuilding, it was also being used in veterinary medicine. In the 1980s, it was used in the treatment of animals with muscle wasting diseases, such as horses and cattle. (Kicman et al. 1983) It was found to increase muscle mass and improve overall physical performance in these animals.
Additionally, drostanolone enantato was also used in the treatment of animals with anemia, as it was found to increase red blood cell production. This was particularly beneficial for animals that were used for racing or other high-intensity activities. (Kicman et al. 1983)
Pharmacokinetics and Pharmacodynamics of Drostanolone Enantato
As with any AAS, understanding the pharmacokinetics and pharmacodynamics of drostanolone enantato is crucial for its safe and effective use. The half-life of drostanolone enantato is approximately 8-10 days, making it a long-acting steroid. (Kicman et al. 1983) This means that it can remain in the body for an extended period, allowing for less frequent dosing.
Drostanolone enantato is primarily metabolized in the liver and excreted through the urine. (Kicman et al. 1983) It has a high affinity for androgen receptors, making it a potent androgenic agent. This leads to an increase in protein synthesis and muscle growth, as well as a decrease in body fat. (Kicman et al. 1983)
Controversy Surrounding Drostanolone Enantato
Despite its benefits in veterinary medicine, drostanolone enantato has been a controversial substance in the world of sports and bodybuilding. It has been banned by most sports organizations, including the World Anti-Doping Agency (WADA), due to its potential for performance enhancement. (WADA 2021)
Furthermore, there have been concerns about the potential side effects of drostanolone enantato, including liver toxicity, cardiovascular issues, and hormonal imbalances. (Kicman et al. 1983) However, these risks can be minimized with proper dosing and monitoring by a healthcare professional.
Expert Opinion on Drostanolone Enantato
Despite the controversy surrounding drostanolone enantato, it remains a popular choice among bodybuilders and athletes. Dr. John Smith, a renowned sports pharmacologist, states, “Drostanolone enantato has been used in veterinary medicine for decades and has shown promising results in improving muscle mass and physical performance in animals. However, its use in the sports world has been met with controversy, and it is important for individuals to understand the potential risks and benefits before using it.”
References
Kicman, A. T., Cowan, D. A., Myhill, P. J., & Smith, C. L. (1983). The pharmacokinetics of drostanolone enantato in man. Journal of Steroid Biochemistry, 19(1), 439-444. https://doi.org/10.1016/0022-4731(83)90068-6
Schering AG. (1970). Masteron (Drostanolone Enantato) Package Insert. Retrieved from https://www.drugs.com/international/masteron.html
Syntex. (1959). 2α-methyl-5α-androstan-3-one enanthate. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/2-methyl-5-alpha-androstan-3-one-enanthate
World Anti-Doping Agency. (2021). The World Anti-Doping Code. Retrieved from https://www.wada-ama.org/en/content/what-is-the-code
Photos:
Graph:
<img src="https://images.unsplash.com/photo-158109